Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1204295 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL15612335 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL9313066 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL5697033 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL9031506 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL474083 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL1330805 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL6388831 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL9633221 | 0.95 | SLC34A1 (0.80) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL11283215 | 0.95 | SLC34A1 (0.80) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066181-A1 | OPHTHALMIC VISCOELASTIC COMPOSITIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-02-29 | — | — | US | claimed |
| EP-3713617-A1 | OPHTHALMIC VISCOELASTIC COMPOSITIONS | Bausch & Lomb Incorporated (US) | 2020-09-30 | — | — | EP | claimed |
| WO-2019103932-A1 | OPHTHALMIC VISCOELASTIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2019-05-31 | — | — | WO | claimed |
| US-20190151500-A1 | OPHTHALMIC VISCOELASTIC COMPOSITIONS | MEDICIS PHARMACEUTICAL CORPORATION | 2019-05-23 | — | — | US | claimed |
| US-20240240047-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024146878-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024145638-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | ELI LILLY AND COMPANY (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3419682-B1 | CRYSTALLIZATION INHIBITOR COMPOSITIONS FOR IMPLANTABLE UROLOGICAL DEVICES | INNOVATIVE SURFACE TECH INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20240066181-A1 | OPHTHALMIC VISCOELASTIC COMPOSITIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-02-29 | — | — | US | disclosed |
| EP-3730531-B1 | EPOXY COMPOUND, COMPOSITION, CURED PRODUCT AND LAMINATE | DAINIPPON INK & CHEMICALS (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-11660370-B2 | Ophthalmic device packaging solutions comprising tris(hydroxymethyl)aminomethane and nonionic surfactant | BAUSCH & LOMB INCORPORATED (US) | 2023-05-30 | — | — | US | disclosed |
| CN-115094052-B | Thermophilic heavy metal ion-tolerant beta-glucosidase and application thereof | 大理大学 | 2023-05-19 | — | — | CN | disclosed |
| EP-0837679-B1 | 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES | GLIATECH INC (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166060-A | 1H-4(5)-substituted imidazole derivatives | GLIATECH, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6008240-A | AN ANTAGONIST OF HISTAMINE H3 RECEPTORS; FOR TREATING ALLERGY, INFLAMMATION, CARDIOVASCULAR DISEASE (HYPER OR HYPOTENSION), GASTROINTESTINAL DISORDERS, CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5990317-A | HISTAMINE H3 RECEPTOR ANTAGONIST FOR TREATING CNS DISORDERS INVOLVING ATTENTION OR COGNITIVE DISORDERS | GLIATECH, INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0841922-A4 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH INC (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0841922-A1 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1996038142-A1 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996030391-A1 | SUBSTITUTED 6-AZACHOLESTEN-3-ONES | GLAXO WELLCOME INC. (US) | 1996-10-03 | — | — | WO | disclosed |